Dr Gloria Gonzalez-Aseguinolaza
Co-Founder & Chief Scientific Officer
Dr Gonzalez-Aseguinolaza scientific career has always been associated with the development of treatments for orphan diseases, she begun working on the development of genetic vaccines against parasitic infections like malaria at the Centro de Investigaciones Biológicas in Madrid, Spain and the University of New York, USA. Then she moved to the field of rare diseases. Dr Gonzalez-Aseguinolaza has been working on hepatic rare diseases for the last 10 years focus on the development on the characterization of animal models, development of new therapeutic strategies and new gene delivery vectors. Her main achievement in the field was the coordination of an European consortium created to perform the first AAV-gene therapy clinical trial for a liver inherited metabolic disease, Acute intermittent porphyria. Since 2014, Dr Gonzalez-Aseguinolaza is the head of the Gene Therapy Program at CIMA and the coordinator of the area of advanced therapies of the institute of biomedical of our Region (Navarra), IdiSNA. Dr. Gonzalez-Aseguinolaza earned her PhD in Science from Universidad Autonoma de Madrid.